Factor VIII concentrates in HIV-1-positive hemophiliacs--is pure better?
39 human immunodeficiency-virus-1 (HIV-1)-positive hemophiliacs who had been regularly treated with non-virus-inactivated intermediate-purity factor VIII concentrates were divided into two groups. Group A consisted of 21 patients with a CD4/CD8 cell ratio of less than 1.0 and group B of 18 patients with a CD4/CD8 cell ratio of greater than 1.0. All patients of group A were switched to a high-purity virus-inactivated factor VIII concentrate, whereas patients of group B continued to receive the intermediate-purity concentrate. There was no significant difference in the average decline of CD4 cells between the two groups during the observation period. 9 patients of group A and 4 patients of group B developed AIDS. 5 patients of group A but 11 patients of group B remained clinically asymptomatic. We conclude that the 15-fold increase in purity of the factor VIII concentrate had no apparent beneficial effect on the CD4 cell counts in this patient group.
Eichinger
S
S
First Department of Internal Medicine, Division of Hematology and Blood Coagulation, Vienna, Austria.
Pabinger
I
I
Kyrle
P A
PA
Köller
U
U
Kier
P
P
Schneider
B
B
Lechner
K
K
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000517:prevention & control; D000293:Adolescent; D000328:Adult; D001798:Blood Proteins / Q000009:adverse effects; D016516:CD4-CD8 Ratio; D002648:Child; D015331:Cohort Studies; D005169:Factor VIII / Q000592:standards / Q000627:therapeutic use*; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications*; D015497:HIV-1; D006467:Hemophilia A / Q000150:complications / Q000628:therapy*; D006358:Hot Temperature; D006801:Humans; D007108:Immune Tolerance; D008297:Male; D008875:Middle Aged
D001798:Blood Proteins; D005169:Factor VIII